FDA launches real-time trial pilot

The Food and Drug Administration said April 28 it has begun testing “real-time clinical trials,” letting reviewers see selected trial signals while studies are still running. (fda.gov) Clinical trials usually send regulators a large package of data after a study phase ends. In the new model, the agency receives pre-agreed endpoints and safety signals as they are generated, instead of waiting months for a full handoff. (fda.gov) (statnews.com) The first two proofs of concept are both cancer trials. AstraZeneca is running a Phase 2 study in previously untreated mantle cell lymphoma, and Amgen is preparing a Phase 1b study called STREAM-SCLC in limited-stage small cell lung carcinoma. (fda.gov) (abcnews.go.com) The FDA said it has already received and validated signals from the AstraZeneca trial through Paradigm Health, which the agency described as proof that the technical setup can work. Paradigm said sites include MD Anderson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. (fda.gov) (paradigmhealth.ai) Commissioner Marty Makary said the goal is to remove “dead time” between trial phases and drug-review steps. Chief Artificial Intelligence Officer Jeremy Walsh said the approach could cut “months, if not years” from development timelines, while the agency still avoids pulling in full patient-level datasets. (usnews.com) (bloomberg.com) The FDA paired the announcement with a request for information on a broader pilot program planned for summer 2026. The agency asked sponsors, contract research groups, data platforms and patient organizations how real-time reporting should work in practice. (fda.gov) The trials are also a test of data plumbing, not just medicine. Companies need systems that can trace where each data point came from, flag changes, and preserve an audit trail that regulators can inspect. (statnews.com) (fiercebiotech.com) The FDA framed the project as a way to speed development and keep U.S. drug regulation competitive with China. For now, the agency is starting with two oncology studies and a summer pilot rather than changing the whole approval system at once. (usnews.com) (fda.gov)